UnicoCell Biomed CoTPE:6794 +4.67%83 Quick Ratio is 37.57 as of Dec. 2025, which is 79% above its 10-year median of 20.94. GuruFocus rates TPE:6794 with a GF Score™ of 83/100 and a GF Value™ of NT$101.57 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,408 Biotechnology companies, UnicoCell Biomed Co ranks better than 97.66% on this metric.
UnicoCell Biomed Co has a quick ratio of 37.57. It generally indicates good short-term financial strength.
The historical rank and industry rank for UnicoCell Biomed Co's Quick Ratio or its related term are showing as below:
TPE:6794'
s Quick Ratio Range Over the Past 10 Years
Min: 7.36 Med: 20.94 Max: 37.57
Current: 37.57
During the past 9 years, UnicoCell Biomed Co's highest Quick Ratio was 37.57. The lowest was 7.36. And the median was 20.94.
TPE:6794's Quick Ratio is ranked better than 97.66% of 1408
companies
in the Biotechnology industry
Industry Median: 3.6
vs TPE:6794: 37.57
UnicoCell Biomed Co (TPE:6794) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
UnicoCell Biomed Co Quick Ratio Related Terms
UnicoCell Biomed Co Quick Ratio Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6794 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, UnicoCell Biomed Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
UnicoCell Biomed Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UnicoCell Biomed Co (TPE:6794) has a Quick Ratio of 37.57 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on UnicoCell Biomed Co and its competitors. This is 79% above median its historical median of 20.94. Over the past decade, UnicoCell Biomed Co's Quick Ratio has ranged from 7.36 to 37.57. According to the industry distribution chart, UnicoCell Biomed Co ranks #33 out of 1408 companies in the Biotechnology industry, placing it in the top 2.3%.
Is UnicoCell Biomed Co's Quick Ratio too high?
UnicoCell Biomed Co's current Quick Ratio of 37.57 is 79% above median its 10-year median of 20.94. Over the past 10 years, this metric has ranged from a low of 7.36 to a high of 37.57. The Biotechnology industry median Quick Ratio is 3.60. UnicoCell Biomed Co's value of 37.57 is 943.6% above this industry median. Based on the distribution chart, UnicoCell Biomed Co ranks #33 out of 1408 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UnicoCell Biomed Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #33 out of 1408 companies for Quick Ratio. This places UnicoCell Biomed Co in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. UnicoCell Biomed Co's value of 37.57 is 943.6% above this benchmark. Historically, UnicoCell Biomed Co's own Quick Ratio has ranged from 7.36 to 37.57 over the past decade. While the company's 10-year median is 20.94 vs. the industry median of 3.60, UnicoCell Biomed Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UnicoCell Biomed Co's current Quick Ratio of 37.57 is 943.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on UnicoCell Biomed Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current Quick Ratio is 37.57, which is 79% above median its own 10-year median of 20.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$101.57, compared to a current price of NT$85.20 — trading 16.1% below its estimated fair value. The current Quick Ratio is 37.57, which is 79% above median its 10-year median of 20.94 and 943.6% above the Biotechnology industry median of 3.60. UnicoCell Biomed Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Quick Ratio is 37.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued.
The current stock price of NT$85.20 is trading 16.1% below its estimated GF Value™ of NT$101.57.
GuruFocus considers UnicoCell Biomed Co to be Modestly Undervalued.
Key valuation signals for TPE:6794:
Quick Ratio: 37.57 (79% above median its 10-year median of 20.94)
GF Value™: NT$101.57 vs. price of NT$85.20 (16.1% below fair value)
Industry Position: 943.6% above the Biotechnology median (#33 of 1408)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
83GF Score
Get the complete analysis for TPE:6794
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
